1. Canadian product monographs for apomorphine and lurbinectedin updated

   News item 04 February 2023 Pages: 1 - 1

2. Ceftriaxone- and cefotaxime-related severe hypersensitivity reactions

   News item 04 February 2023 Pages: 2 - 2

3. Cephalosporin-related seizures

   News item 04 February 2023 Pages: 3 - 3

4. Contaminated Indian cough syrups identified in WHO European region

   News item 04 February 2023 Pages: 4 - 4

5. Finasteride: potential risks of suicidal ideation and self-injury

   Review 04 February 2023 Pages: 5 - 5

6. Incorrect labelling on cartons of isoflurane

   News item 04 February 2023 Pages: 6 - 6

7. MHRA advises caution in switching metolazone preparations

   News item 04 February 2023 Pages: 7 - 7

8. Omeprazole suspension Pedippi should be with diluted with milk

   News item 04 February 2023 Pages: 8 - 8

9. WHO calls for action to prevent use of contaminated medicines in children

   News item 04 February 2023 Pages: 9 - 9

10. FAERS data may drive measures to prevent suicide by intentional overdose

    Clinical study 04 February 2023 Pages: 10 - 10

11. Risk of angioedema with sacubitril/valsartan versus ACE inhibitors and ARBs

    Clinical study 04 February 2023 Pages: 11 - 11

12. Risk of SGLT2i-related AEs not greater in elderly versus younger adults

    Clinical study 04 February 2023 Pages: 12 - 12

13. Other adverse reaction research

    News item 04 February 2023 Pages: 13 - 13

14. Abiraterone acetate/prednisone

    Case report 04 February 2023 Pages: 14 - 14

15. Acetazolamide/eldecalcitol

    Case report 04 February 2023 Pages: 15 - 15

16. Acitretin/ruxolitinib

    Case report 04 February 2023 Pages: 16 - 16

17. Ad26.cov2-s/elasomeran

    Case report 04 February 2023 Pages: 17 - 17

18. Afatinib/gefitinib

    Case report 04 February 2023 Pages: 18 - 18

19. Albumin-human/furosemide

    Case report 04 February 2023 Pages: 19 - 19

20. Aminocaproic-acid/factor-VIII/von-Willebrand-factor

    Case report 04 February 2023 Pages: 20 - 20

21. Amiodarone

    Case report 04 February 2023 Pages: 21 - 21

22. Amlodipine

    Case report 04 February 2023 Pages: 22 - 22

23. Amphotericin-B liposomal/miltefosine

    Case report 04 February 2023 Pages: 23 - 23

24. Anagrelide/aspirin/hydroxycarbamide

    Case report 04 February 2023 Pages: 24 - 24

25. Analgesics/Nonsteroidal-anti-inflammatories

    Case report 04 February 2023 Pages: 25 - 25

26. Antiarrhythmics/beta-adrenergic-receptor-antagonists/hypnosedatives

    Case report 04 February 2023 Pages: 26 - 26

27. Antibacterials

    Case report 04 February 2023 Pages: 27 - 27

28. Antibacterials/glucocorticoids

    Case report 04 February 2023 Pages: 28 - 28

29. Antibacterials/norepinephrine/tozinameran

    Case report 04 February 2023 Pages: 29 - 29

30. Antiemetics/erythromycin/omeprazole

    Case report 04 February 2023 Pages: 30 - 30

31. Antihypertensives/sufentanil

    Case report 04 February 2023 Pages: 31 - 31

32. Antihypotensive/sodium-chloride/vasopressin

    Case report 04 February 2023 Pages: 32 - 32

33. Antineoplastic drugs

    Case report 04 February 2023 Pages: 33 - 33

34. Antineoplastics

    Case report 04 February 2023 Pages: 34 - 34

35. Antineoplastics

    Case report 04 February 2023 Pages: 35 - 35

36. Antineoplastics

    Case report 04 February 2023 Pages: 36 - 36

37. Antineoplastics

    Case report 04 February 2023 Pages: 37 - 37

38. Antineoplastics

    Case report 04 February 2023 Pages: 38 - 38

39. Antineoplastics

    Case report 04 February 2023 Pages: 39 - 39

40. Antineoplastics

    Case report 04 February 2023 Pages: 40 - 40

41. Antineoplastics

    Case report 04 February 2023 Pages: 41 - 41

42. Antineoplastics

    Case report 04 February 2023 Pages: 42 - 42

43. Antineoplastics

    Case report 04 February 2023 Pages: 43 - 43

44. Antineoplastics

    Case report 04 February 2023 Pages: 44 - 44

45. Antineoplastics/apixaban/dexamethasone

    Case report 04 February 2023 Pages: 45 - 45

46. Antineoplastics/diuretics

    Case report 04 February 2023 Pages: 46 - 46

47. Antineoplastics/folinic acid

    Case report 04 February 2023 Pages: 47 - 47

48. Antineoplastics/hydrocortisone

    Case report 04 February 2023 Pages: 48 - 48

49. Antineoplastics/Lutetium-177-psma-imaging-and-therapy

    Case report 04 February 2023 Pages: 49 - 49

50. Antineoplastics/oxycodone/fentanyl

    Case report 04 February 2023 Pages: 50 - 50